TAKHZYRO™ (lanadelumab-flyo) injection is a monoclonal antibody preventive treatment for hereditary angioedema (HAE) in patients 12 yrs and older. HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of edema (swelling in various parts of the body).
TAKHZYRO™ (lanadelumab-flyo) injection is a monoclonal antibody preventive treatment for hereditary angioedema (HAE) in patients 12 yrs and older. HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of edema (swelling in various parts of the body).